Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Varilrix (inactivated varicella vaccine)
Varilrix · 1 trial · 1 indication
Antibody titers have been assessed by immunofluorescence assay (IFA) and presented as geometric mean titers (GMTs), for initially seronegative subjects \[with anti-VZV titer below (\<) 1:4\].
Antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), for initially seronegative subjects \[with anti-VZV concentration below (\<) 25 mIU/mL\].
| Arm | Type | Description |
|---|---|---|
| VARILRIX HSA-FREE GROUP | EXPERIMENTAL | Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine produced without human serum albumin (HSA-Free), administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6). |
| VARILRIX GROUP | EXPERIMENTAL | Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine, administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6). |
| Name | Type | Description |
|---|---|---|
| Varilrix (inactivated varicella vaccine) | BIOLOGICAL | subcutaneously injection |
Inclusion Criteria: * Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) should be enrolled in the study. * A male or female between, and including, 11 and 21...
Varilrix is a varicella vaccine developed by GSK plc for the prevention of varicella, commonly known as chickenpox. It is an inactivated varicella vaccine studied in healthy volunteers, including young children from 11 months of age, in a Phase 2 clinical program.
Varilrix is developed by GSK plc, which trades under the ticker GSK. GSK Biologicals conducted the clinical study of two formulations of the vaccine. GSK plc is the sponsor and manufacturer associated with the Varilrix varicella vaccine asset.
Varilrix is in Phase 2 clinical development. One Phase 2 trial has been completed, and no active trials are currently listed. The completed study was a randomized, double-blind, controlled trial of two formulations of GSK Biologicals' varicella vaccine.
Varilrix has been studied in one completed Phase 2 trial, NCT00568334, titled Study of Two Formulations of GSK Biologicals' Varicella Vaccine. The trial enrolled 244 healthy volunteers aged 11 months and older in Czechia and Hungary and was randomized, double-blind, and controlled.
Yes. Varilrix is also known as inactivated varicella vaccine and is sometimes written as Varilrix. These names refer to the same GSK plc vaccine asset for varicella. Searches for either name point to the same Phase 2 program.